Journal Watch · Neuron · 2026

Targeting PGAM5-driven mitochondrial integrated stress response slows ALS progression across subtypes.

These findings establish PGAM5 as a convergent and actionable therapeutic target across ALS subtypes.

Zheng Z, Yang W, Chen Z et al.Neuron3 min readPharma relevance 85/100

DOI: 10.1016/j.neuron.2026.02.003PMID: 41819100Study type: preclinical (animal / model) study

TL;DR

These findings establish PGAM5 as a convergent and actionable therapeutic target across ALS subtypes.

Key findings

  • The disruption of PGAM5-OMA1 interaction by a selective inhibitor (TAT-PO1) or pharmacological inhibition of PGAM5 with telmisartan suppresses mtISR activation and ameliorates ALS-related phenotypes by reshaping mtISR outputs in a manner distinct from those elicited by activation of translation initiation factor 2B (eIF2B).
  • These findings establish PGAM5 as a convergent and actionable therapeutic target across ALS subtypes.

What they did

PGAM5 activates the mitochondrial integrated stress response (mtISR) via dephosphorylation of metallopeptidase OMA1 at Ser223 and Ser237, thereby driving neuromuscular junction disruption and motor deficits. We show that PGAM5 is a substrate of valosin-containing protein (VCP) and is consistently elevated in spinal cords from sporadic ALS patients, in human spinal cord organoids derived from sporadic or familial ALS, and in ALS mouse models.

Full abstract (original)

Background: Amyotrophic lateral sclerosis (ALS) is genetically and clinically heterogeneous, yet convergent pathogenic mechanisms remain poorly defined. A CRISPR-Cas9 screen identified phosphoglycerate mutase-5 (PGAM5) as a common mediator of ALS pathogenesis.

What they did: PGAM5 activates the mitochondrial integrated stress response (mtISR) via dephosphorylation of metallopeptidase OMA1 at Ser223 and Ser237, thereby driving neuromuscular junction disruption and motor deficits. We show that PGAM5 is a substrate of valosin-containing protein (VCP) and is consistently elevated in spinal cords from sporadic ALS patients, in human spinal cord organoids derived from sporadic or familial ALS, and in ALS mouse models.

Results & conclusions: The disruption of PGAM5-OMA1 interaction by a selective inhibitor (TAT-PO1) or pharmacological inhibition of PGAM5 with telmisartan suppresses mtISR activation and ameliorates ALS-related phenotypes by reshaping mtISR outputs in a manner distinct from those elicited by activation of translation initiation factor 2B (eIF2B). These findings establish PGAM5 as a convergent and actionable therapeutic target across ALS subtypes.

Abstract © the authors / Neuron (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.neuron.2026.02.003 · PubMed 41819100.

Why it matters for pharma & biotech

  • Directly relevant to teams in gene editing, small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: gene editing · small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Neuron study find?

These findings establish PGAM5 as a convergent and actionable therapeutic target across ALS subtypes.

What type of study is this?

It is a preclinical (animal / model) study, published in Neuron in 2026. PGAM5 activates the mitochondrial integrated stress response (mtISR) via dephosphorylation of metallopeptidase OMA1 at Ser223 and Ser237, thereby driving neuromuscular junction disruption and motor deficits.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.neuron.2026.02.003. PubMed ID: 41819100. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Zheng Z, Yang W, Chen Z et al.. Targeting PGAM5-driven mitochondrial integrated stress response slows ALS progression across subtypes.. Neuron (2026). DOI: 10.1016/j.neuron.2026.02.003.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/targeting-pgam5-driven-mitochondrial-integrated-stress-response-slows-al-602003/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides